Atria Investments Inc Has $221,000 Stock Position in LivaNova PLC $LIVN

Atria Investments Inc trimmed its stake in LivaNova PLC (NASDAQ:LIVN) by 55.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,912 shares of the company’s stock after selling 6,103 shares during the period. Atria Investments Inc’s holdings in LivaNova were worth $221,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in LIVN. CWM LLC lifted its stake in shares of LivaNova by 52.3% in the first quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after buying an additional 299 shares during the period. GAMMA Investing LLC lifted its position in shares of LivaNova by 182.5% in the 2nd quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after acquiring an additional 407 shares during the period. Central Pacific Bank Trust Division grew its holdings in shares of LivaNova by 9.5% during the 2nd quarter. Central Pacific Bank Trust Division now owns 4,827 shares of the company’s stock worth $217,000 after purchasing an additional 420 shares in the last quarter. Retirement Systems of Alabama raised its stake in shares of LivaNova by 0.8% in the second quarter. Retirement Systems of Alabama now owns 66,644 shares of the company’s stock valued at $3,000,000 after purchasing an additional 554 shares in the last quarter. Finally, Hsbc Holdings PLC raised its stake in shares of LivaNova by 13.4% in the first quarter. Hsbc Holdings PLC now owns 6,666 shares of the company’s stock valued at $258,000 after purchasing an additional 790 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LIVN. Barclays boosted their price target on shares of LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of LivaNova in a research report on Wednesday, September 3rd. The Goldman Sachs Group set a $55.00 target price on shares of LivaNova and gave the company a “neutral” rating in a research note on Wednesday, October 1st. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Finally, Mizuho lifted their price objective on LivaNova from $65.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $62.43.

LivaNova Stock Down 2.5%

LIVN opened at $55.20 on Friday. The firm has a market cap of $3.01 billion, a price-to-earnings ratio of -14.19 and a beta of 1.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The firm’s 50-day simple moving average is $53.76 and its 200-day simple moving average is $48.73. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $58.91.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.20. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The business had revenue of $357.80 million for the quarter, compared to analyst estimates of $342.32 million. During the same period in the prior year, the company earned $0.90 EPS. LivaNova’s revenue for the quarter was up 12.5% on a year-over-year basis. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. Equities research analysts anticipate that LivaNova PLC will post 2.85 EPS for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.